Inovio Pharmaceuticals, Inc. (INO)

Oncology Corporate Profile

Stock Performance

5.9600
-0.0500

HQ Location

1787 Sentry Parkway West, Building 18, Suite 400
Blue Bell, PA 19422

Company Description

Inovio Pharmaceuticals, Inc. is focused on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.

Website: http://www.inovio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Selective Electrochemical Tumor Ablation (SECTA) + (bleomycin)electroporation therapy2nd line metastatic Breast cancerI
INO-3112cancer therapeutic vaccineAerodigestive cancerI
INO-1400hTERT immunotherapyBreast cancerI
INO-3112cancer therapeutic vaccineCervical cancerI
INO-3112cancer therapeutic vaccineHead & Neck cancerI
INO-1400hTERT immunotherapyNon Small Cell Lung Cancer (NSCLC)I
INO-1400hTERT immunotherapyPancreatic cancerI
INO-5150immunotherapyProstate cancerI
V930DNA vaccineVarious cancer typesIMerck Serono
INO-3106immunotherapyVarious cancer typesI

View additional information on product candidates here »

Source: http://www.inovio.com

Recent News Headlines

Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

10/24/2016 11:58 am

(Yahoo! Finance) Oct 24, 2016 - Inovio Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notification issued by the FDA to a trial sponsor to delay a proposed clinical trial or suspend an ongoing clinical trial. This study has not yet been initiated and has not enrolled or dosed subjects. Additionally, the hold does not pertain to any of Inovio’s other ongoing clinical studies.

Radiation and Vaccination Can Magnify Effects Of Immunotherapy

6/14/2016 11:05 am

(University of Chicago Medicine) June 13, 2016 - By combining local radiation therapy and anti-cancer vaccines with checkpoint inhibitors, researchers from the University of Chicago, working with mice, were able to increase the response rate for these new immunotherapy agents.

Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer

11/6/2015 11:35 am

(TheStreet) Nov 5, 2015 - Inovio Pharmaceuticals, Inc. announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

8/21/2015 12:19 pm

(TheStreet) Aug 21, 2015 - Biotech columnist Adam Feuerstein answers readers' questions about health care.

AstraZeneca Bags Another Cancer Drug Deal, This Time With Inovio

8/10/2015 12:24 pm

(Reuters) Aug 10, 2015 - AstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals.

AstraZeneca to Pay Inovio Up to $700 Million for Cancer Drug

8/10/2015 06:46 am

(Bloomberg) Aug 10, 2015 - AstraZeneca Plc agreed to pay Inovio Pharmaceuticals Inc. as much as $727.5 million for rights to an experimental cancer vaccine, its third deal in a week to secure access to new tumor-fighting drugs.

Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer

7/27/2015 11:52 am

(MarketWatch) July 27, 2015 - Inovio Pharmaceuticals, Inc. announced today that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in men with biochemically relapsed prostate cancer.

Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial

7/23/2015 11:41 am

(Yahoo! Finance) July 23, 2015 - Inovio Pharmaceuticals, Inc. announced today that it is collaborating with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate Inovio's immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer.

Genetic Expression 'Predicts Lung Cancer Survival’

7/15/2015 11:03 am

(University of Oxford [UK]) July 13, 2015 - A study led by Oxford University researchers and colleagues at the National Cancer Institute, Milan, Italy has shed light on a key puzzle thrown up in some lung cancer screening programmes.

Inovio Pharmaceuticals HPV Immunotherapy Activates Robust in Vivo T Cell Responses in Head & Neck Cancer Patients

4/9/2015 11:57 am

(Yahoo! Finance) Apr 9, 2015 - Inovio Pharmaceuticals, Inc. announced today preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.

Lilly to Test Combinations with Merck, Bristol-Myers' Cancer Drugs

1/13/2015 11:02 am

(Reuters) Jan 13, 2015 - Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

11/17/2014 11:27 am

(TheStreet) Nov 17, 2014 - Inovio Pharmaceuticals, Inc. announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer.

Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers

9/23/2014 10:56 am

(Philadelphia Business Journal) Sept 22, 2014 - Inovio Pharmaceuticals, Inc. announced today it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106.

Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial

9/16/2014 07:03 am

(Forbes) Sept 15, 2014 - Merck's "heir to Fosamax," odanacatib, performs well in preventing fractures in a long, large trial with postmenopausal women over 65 suffering from osteoporosis.

With So Many Terrific New Drugs For Chronic Lymphocytic Leukemia, Why Worry?

8/29/2014 05:01 am

(Forbes) Aug 28, 2014 - It’s hard to keep track of practice-changing drugs for chronic lymphocytic leukemia (CLL). Since last November, the FDA has approved three new agents and expanded indications for another to treat this indolent cancer of white blood cells.

Herbert Irving Comprehensive Cancer Center Has Designation Renewed by National Cancer Institute; Awarded $18M Grant

8/27/2014 06:05 am

(CUMC) Aug 27, 2014 — Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI).

When Hospitals Buy Clinics, Prices Go Up

7/25/2014 06:05 am

(BloombergBusinessweek) July 24, 2014 - For the past four years, Pennsylvania insurance company Highmark has watched its bills for cancer care skyrocket.

Inovio Pharma's Drug to Treat Cervical Lesions Meets Trial Goal

7/23/2014 11:46 am

(Reuters) July 23, 2014 - Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial.

Inovio Pharma's Drug to Treat Cervical Lesions Meets Trial Goal

7/23/2014 06:04 am

(Reuters) July 23, 2014 - Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial.

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial

6/23/2014 12:13 pm

(Yahoo! Finance) June 23, 2014 - Inovio Pharmaceuticals, Inc. today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer.

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial

6/23/2014 07:01 am

(Yahoo! Finance) June 23, 2014 - Inovio Pharmaceuticals, Inc. today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer.

Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology

6/11/2014 12:00 pm

(Inovio) June 11, 2014 - Inovio Pharmaceuticals, Inc. wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious.

Inovio CEO Preps Retail Investors for Drug Study Failure

6/11/2014 11:59 am

(TheStreet) June 10, 2014 - Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions.

Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology

6/11/2014 07:00 am

(Inovio) June 11, 2014 - Inovio Pharmaceuticals, Inc. wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious.

Inovio CEO Preps Retail Investors for Drug Study Failure

6/11/2014 06:05 am

(TheStreet) June 10, 2014 - Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

1/3/2014 11:52 am

(The Street) Jan 3, 2014 - Happy New Year and welcome back to the Biotech Stock Mailbag. Today marks the start of the eighth year for this column, which wouldn't be possible without your questions and comments. Thank you so much.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

1/3/2014 11:05 am

(The Street) Jan 3, 2014 - Happy New Year and welcome back to the Biotech Stock Mailbag. Today marks the start of the eighth year for this column, which wouldn't be possible without your questions and comments. Thank you so much.

J&J-Medivir Hepatitis C Pills Wins U.S. Panel Backing

10/25/2013 12:01 pm

(Bloomberg) Oct 24, 2013 - Johnson & Johnson and Medivir’s experimental hepatitis C treatment should be approved, advisers to the U.S. government said, propelling the companies into a position to enter a competitive market for new drugs.

Women with Breast Cancer May Overestimate Secondary Risks

9/17/2013 06:03 am

(Reuters Health) Sep 16, 2013 - Young women with breast cancer often overestimate both their chance of developing cancer in the other breast and how much removal of that breast is likely to protect them, a new U.S. study suggests.

Roche Boosts Immunotherapy with Inovio Deal

9/10/2013 06:37 am

(Reuters) Sep 10, 2013 - Swiss drugmaker Roche has struck an exclusive global licensing deal with Inovio Pharmaceuticals to develop vaccines to fight cancer and hepatitis B.

Roche Boosts Immunotherapy with Inovio Deal

9/10/2013 06:03 am

(Reuters) Sep 10, 2013 - Swiss drugmaker Roche has struck an exclusive global licensing deal with Inovio Pharmaceuticals to develop vaccines to fight cancer and hepatitis B.

Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail

8/9/2013 10:20 am

(TheStreet) Aug 9, 2013 – Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail

8/9/2013 10:02 am

(TheStreet) Aug 9, 2013 – Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Myriad Expands Its Patient Financial Assistance Program

7/16/2013 12:00 pm

(Yahoo! Finance) July 15, 2013 - Myriad Genetics, Inc. today announced a program to provide financial assistance to underinsured patients.

Crucial Legislation Would Improve Cancer Patients’ Quality of Life

4/24/2013 11:05 am

(ACS CAN) Apr 23, 2013 - Rep. Emanuel Cleaver (D-Mo.) and Rep. Spencer Bachus (R-Ala.) introduced legislation today that would improve the experience of cancer patients and their families by better coordinating their care and addressing the often debilitating symptoms of treatment.

Biotech Industry at Stake in Human Gene Patent Decision

4/12/2013 09:04 am

(BloombergBusinessweek) Apr 12, 2013 - For 30 years, biotechnology innovators have secured thousands of U.S. patents on genes, defining the legal rights to medical and agricultural products worth hundreds of billions of dollars.

Uterine Cancer Tied to Later Colon Cancer - Study

4/12/2013 09:04 am

(Reuters Health) Apr 11, 2013 - Depending on their age, women diagnosed with uterine cancer may have a higher risk of developing colon cancer later on, according to a new study from Canada.

Celgene Says FDA Panel Won't Review Pomalidomide

10/4/2012 09:05 am

(CBS News/Associated Press) Oct 3, 2012 - Celgene Corp. said Wednesday that a Food and Drug Administration panel will not review its multiple myeloma drug pomalidomide in November.

Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths

7/10/2012 08:00 am

[PR Newswire] - BLUE BELL, Pa., July 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly ...

Inovio Pharmaceuticals to Present at JMP Investor Conference

7/9/2012 08:00 am

[PR Newswire] - BLUE BELL, Pa., July 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the JMP Securities ...

Inovio Pharmaceuticals Appoints International Management Expert Dr. Angel Cabrera to its Board of Directors

6/18/2012 08:00 am

[PR Newswire] - BLUE BELL, Pa., June 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has appointed Angel Cabrera, Ph.D., to its Board of Directors. Dr. Cabrera is outgoing president of the Thunderbird ...